Приказ основних података о документу
Procurement of Cytostatics in the Republic of Srpska
| dc.creator | Kopanja, Đurđica | |
| dc.creator | Zrilić, Mira | |
| dc.creator | Kundaković, Tatjana | |
| dc.date.accessioned | 2024-01-22T15:00:40Z | |
| dc.date.available | 2024-01-22T15:00:40Z | |
| dc.date.issued | 2019 | |
| dc.identifier.uri | https://farfar.pharmacy.bg.ac.rs/handle/123456789/5499 | |
| dc.description.abstract | In 2017, there were 36 543 patients with cancer in the hospitals in Republic of Srpska (RS). The trend for the growth of diseased patients of younger age is evident.The costs for cytostatics in 2017 year amounted to 14,31millions EUR. Procurement of cytostatics at the tertiary level of healthcare is provided through the Health Insurance Fund of Republic of Srpska and has been conducted through public procurement. Very often there are the shortages of cytostatics in the hospitals. The patients are forced to take over the procurement of these drugs themselves. Patients are forced to buy drugs in other countries. | sr |
| dc.language.iso | en | sr |
| dc.publisher | International Pharmaceutical Federation (FIP) | sr |
| dc.rights | openAccess | sr |
| dc.source | 79th FIP World Congress of Pharmacy and Pharmaceutical Sciences, 22-26 September, 2019. Abu Dhabi, United Arab Emirates | sr |
| dc.subject | cytostatics | sr |
| dc.subject | Republic of Srpska | sr |
| dc.title | Procurement of Cytostatics in the Republic of Srpska | sr |
| dc.type | conferenceObject | sr |
| dc.rights.license | ARR | sr |
| dc.description.other | FIP 2019 Abu Dhabi | sr |
| dc.description.other | Poster presentation | |
| dc.identifier.fulltext | http://farfar.pharmacy.bg.ac.rs/bitstream/id/15503/Procurement_of_cytostatics_pub_2019.pdf | |
| dc.identifier.rcub | https://hdl.handle.net/21.15107/rcub_farfar_5499 | |
| dc.type.version | publishedVersion | sr |
